MUSC researchers show that patients with scleroderma and lung fibrosis have too little of the antifibrotic protein Cathepsin L. This finding opens new pathways for therapeutic intervention by focusing on increasing antifibrotic proteins rather than just reducing profibrotic ones.
Read Full ArticleResearch team identifies the mechanism by which the E4 peptide reverses fibrosis in multiple organs. The peptide activates the urokinase pathway, providing a possible clinical solution for patients with fibrosis across different organ systems.
Read Full ArticleLysyl oxidase (LOX) plays multiple important roles in promoting fibrosis and shows promise as a biomarker for monitoring treatment response. This "moonlighting" molecule offers new insights into disease progression and therapeutic monitoring.
Read Full Article